Cigna Corporation · CI · Next earnings

Cigna Corporation reports Thursday, Oct 29, 2026

CI reports before market open with consensus EPS at $7.51 and revenue at $72.65B. Last quarter: Cigna Beats Q1 Estimates, Raises Full-Year EPS Guidance on Specialty Strength and AI Investments

Reports Before market open39 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $7.51 Calendar consensus
Consensus revenue $72.65B Calendar consensus
Report date Oct 29, 2026 Thursday, date estimated
Session Before market open 39 days away

Where CI left off: FY2026 Q1

Full report

Cigna Beats Q1 Estimates, Raises Full-Year EPS Guidance on Specialty Strength and AI Investments

EPS surprise +2.5% Reported $7.79 vs $7.60
Revenue surprise +3.3% Reported $68.49B vs $66.29B
Stock move -0.6% Event window
Subsequent drift -4.5% Up to 20 sessions

Management raised full-year adjusted EPS guidance to at least $30.35. The transcript analysis characterized guidance sentiment as 'raised.' No prior guidance figure was available in the supplied facts for direct comparison, but the direction is unambiguously upward. Capex outlook was not mentioned.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Rising pharmaceutical costs and inflationary pressure from new drug launches could compress margins.
  • Regulatory and legislative changes affecting pharmacy benefit services and prior-authorization processes.
  • Execution risk in the Signature model rollout and integration of recent acquisitions.
  • Market volatility affecting employer benefit spending.
  • Leadership transition adds uncertainty during a period of significant portfolio change.

Questions analysts left open

  • Timing and client lead-time required for the transition to the Signature pharmacy model.
  • Capital impact and materiality of exiting the individual exchange business.
  • Potential valuation and transaction structure for eviCore strategic alternatives.
  • Sustainability of specialty growth and biosimilar adoption rates.
  • GLP-1 drug utilization trends and associated cost pressures.

Ask FN2 about CI next report

Transcript, numbers and history already loaded
What should I watch for in CI's next earnings report?How did CI guide last quarter, and is consensus above or below that?Give me the bull and bear case going into CI earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the CI recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent CI quarters

All CI earnings
-0.6%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.